Brintellix

Brintellix (Vortioxetine Hydrobromide) is a modern antidepressant that is used to treat large depressive episodes in adults. The mechanism of action of Brintellix (Vortioxetine Hydrobromide) is associated with its direct modulating serotonergic activity and inhibition of the serotonin transporter protein. Brintellix (Vortioxetine Hydrobromide) corrects neurotransmission in several systems, primarily serotonergic, but probably also noradrenergic, dopaminergic, neurotransmission mediated by histamine, acetylcholine, GABA and glutamate. Such broad pharmacological activity underlies the antidepressant and anxiolytic properties of vortioxetine, and also contributes to the improvement of cognitive functions, learning and memory.

Always follow your doctor`s instructions when using Brintellix (Vortioxetine Hydrobromide) to get the safest and most effective results from treatment. Typically, initial and recommended dose of Brintellix (Vortioxetine Hydrobromide) is 10 mg once a day, regardless of food intake. Depending on the individual reaction of the patient, the daily dose of Brintellix (Vortioxetine Hydrobromide) can be increased to a maximum dose of 20 mg/day.

After the symptoms of depression are fully resolved, it is recommended that treatment be continued for at least 6 months to consolidate the antidepressant effect.

Patients receiving treatment with Brintellix (Vortioxetine Hydrobromide) may immediately stop taking it without the need for a gradual dose reduction.

The use of Brintellix (Vortioxetine Hydrobromide) may cause side effects in some patients including:

• nausea
• unusual dreams
• dizziness
• diarrhea, constipation, vomiting
• itching, including generalized
• night sweat

Contact your doctor immediately if you experience any serious or worrying symptoms.

During therapy with Brintellix (Vortioxetine Hydrobromide), alcohol intake is not recommended.

There is limited data on the use of Brintellix (Vortioxetine Hydrobromide) during pregnancy. The drug Brintellix (Vortioxetine Hydrobromide) should not be used during pregnancy, unless the clinical condition of the woman herself requires it.

The risk for the baby during breastfeeding cannot be excluded.

The decision to stop breastfeeding or to abstain from using Brintellix (Vortioxetine Hydrobromide) should be made taking into account the assessment of the relative benefits of breastfeeding for the baby and the need for therapy for the mother.

Brintellix (Vortioxetine Hydrobromide) does not have or has very little effect on the ability to drive a car or machinery. However, patients should be careful when driving vehicles or when working with dangerous machinery, especially at the beginning of treatment with vortioxetine or when changing its dose.